Small Molecule and Biotechnology-Based Therapeutics for Immunology: 2021 IPO Review Pt. VI

This article is Part VI of a review series covering all the initial public offerings for the biotech and pharmaceutical industries in 2021. Pt. I and Pt. II provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Pt. III and Pt. IV provided a deep dive into the 2021 IPOs for oncology-focused companies, while P.t V provided a deep dive into the 2021 IPOs for neurology-focused companies.

This short article takes a deeper look into the 2021 IPOs for small molecule and biotechnology-based therapeutics being developed by immunology-focused companies, including:

  • S1P1 modulators for inflammatory diseases
  • An IL-17 antagonist from DEL screening
  • An immune cell-based therapy
  • An anti-TL1A antibody 
  • And more

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!